CHAIN features in new BIA Life Sciences report
CHAIN’s drug delivery platform and lead product, β-hydroxybutyrate, is highlighted in a new report ‘Catalysing Investment...
read more
CHAIN Biotechnology Ltd was founded by Dr Edward Green in 2014 to develop new Clostridium-based microbial technology for high value healthcare products. CHAIN produces novel live biotherapeutic products (LBPs) for chronic gut-related diseases, such as Inflammatory Bowel Disease (IBD).
At the heart of CHAIN’s unique therapeutic platform is a suite of underpinning technologies including a Clostridia culture collection, a proprietary set of plasmid vectors, synthetic biology tools for advanced metabolic engineering, and an advanced in-vivo delivery mechanism using Clostridium.